Abstract | OBJECTIVE: METHODS: RESULTS: During the median follow-up period of 5.5 years, a statistically significant difference in the 5-year overall survival was noted between patients with N0-1 (n=14) and N2b-3 disease (n=27). One-half of deaths were observed to be the result of distant metastasis. The 5-year local control and overall survival were significantly better in patients with unilateral than in those with bilateral primary tumors. All the patients with T4b disease (n=3) died of disease within 2 years. CONCLUSION: Indications for RADPLAT in patients with HPC were defined as patients with unilateral tumors staged as T3-4a and N0-1.
|
Authors | Jun Furusawa, Akihiro Homma, Rikiya Onimaru, Tomohiro Sakashita, Daisuke Yoshida, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda |
Journal | Auris, nasus, larynx
(Auris Nasus Larynx)
Vol. 42
Issue 6
Pg. 443-8
(Dec 2015)
ISSN: 1879-1476 [Electronic] Netherlands |
PMID | 25933585
(Publication Type: Clinical Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Antineoplastic Agents
- Cisplatin
|
Topics |
- Aged
- Antineoplastic Agents
(therapeutic use)
- Carcinoma, Squamous Cell
(pathology, therapy)
- Chemoradiotherapy
(methods)
- Cisplatin
(therapeutic use)
- Cohort Studies
- Female
- Head and Neck Neoplasms
(pathology, therapy)
- Humans
- Hypopharyngeal Neoplasms
(pathology, therapy)
- Infusions, Intra-Arterial
- Male
- Middle Aged
- Neoplasm Staging
- Retrospective Studies
- Squamous Cell Carcinoma of Head and Neck
- Survival Rate
|